Supporting Information
Additional supporting information may be found online in the Supporting Information section at the end of article.
Appendix S1. Local recurrence free survival of all investigated patients.
Appendix S2. Metastasis recurrence free survival of all investigated patients.
Appendix S3. Disease free survival of all investigated patients.
Appendix S4. Cancer special survival of all investigated patients.
References
1. Chemoradiotherapy for Cervical Cancer Meta-analysis C. Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: individual patient data meta-analysis. The Cochrane database of systematic reviews. 2010 Jan 20(1):CD008285.
2. Green J, Kirwan J, Tierney J, Vale C, Symonds P, Fresco L, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. The Cochrane database of systematic reviews. 2005 Jul 20(3):CD002225.
3. Green JA, Kirwan JM, Tierney JF, Symonds P, Fresco L, Collingwood M, et al. Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: a systematic review and meta-analysis. Lancet. 2001 Sep 8;358(9284):781-6.
4. Rose PG, Bundy BN, Watkins EB, Thigpen JT, Deppe G, Maiman MA, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. The New England journal of medicine. 1999 Apr 15;340(15):1144-53.
5. Nakano T, Kato S, Ohno T, Tsujii H, Sato S, Fukuhisa K, et al. Long-term results of high-dose rate intracavitary brachytherapy for squamous cell carcinoma of the uterine cervix. Cancer. 2005 Jan 1;103(1):92-101.
6. Nag S, Cardenes H, Chang S, Das IJ, Erickson B, Ibbott GS, et al. Proposed guidelines for image-based intracavitary brachytherapy for cervical carcinoma: report from Image-Guided Brachytherapy Working Group. International journal of radiation oncology, biology, physics. 2004 Nov 15;60(4):1160-72.
7. Potter R, Tanderup K, Schmid MP, Jurgenliemk-Schulz I, Haie-Meder C, Fokdal LU, et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): a multicentre prospective cohort study. Lancet Oncol. 2021 Apr;22(4):538-47.
8. Potter R, Georg P, Dimopoulos JC, Grimm M, Berger D, Nesvacil N, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol. 2011 Jul;100(1):116-23.
9. Fallon J, Park SJ, Yang L, Veruttipong D, Zhang M, Van T, et al. Long term results from a prospective database on high dose rate (HDR) interstitial brachytherapy for primary cervical carcinoma. Gynecol Oncol. 2016 Oct 29.
10. Tan LT, Potter R, Sturdza A, Fokdal L, Haie-Meder C, Schmid M, et al. Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study. International journal of radiation oncology, biology, physics. 2019 Jul 15;104(4):895-902.
11. Han K, Milosevic M, Fyles A, Pintilie M, Viswanathan AN. Trends in the utilization of brachytherapy in cervical cancer in the United States. International journal of radiation oncology, biology, physics. 2013 Sep 1;87(1):111-9.
12. Gill BS, Lin JF, Krivak TC, Sukumvanich P, Laskey RA, Ross MS, et al. National Cancer Data Base analysis of radiation therapy consolidation modality for cervical cancer: the impact of new technological advancements. International journal of radiation oncology, biology, physics. 2014 Dec 1;90(5):1083-90.
13. Hanks GE, Herring DF, Kramer S. Patterns of care outcome studies. Results of the national practice in cancer of the cervix. Cancer. 1983 Mar 1;51(5):959-67.
14. Coia L, Won M, Lanciano R, Marcial VA, Martz K, Hanks G. The Patterns of Care Outcome Study for cancer of the uterine cervix. Results of the Second National Practice Survey. Cancer. 1990 Dec 15;66(12):2451-6.
15. Tod M, Meredith WJ. Treatment of cancer of the cervix uteri, a revised Manchester method. The British journal of radiology. 1953 May;26(305):252-7.
16. Kim RY, Pareek P. Radiography-based treatment planning compared with computed tomography (CT)-based treatment planning for intracavitary brachytherapy in cancer of the cervix: analysis of dose-volume histograms. Brachytherapy. 2003;2(4):200-6.
17. Fellner C, Potter R, Knocke TH, Wambersie A. Comparison of radiography- and computed tomography-based treatment planning in cervix cancer in brachytherapy with specific attention to some quality assurance aspects. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2001 Jan;58(1):53-62.
18. Murakami N, Kasamatsu T, Wakita A, Nakamura S, Okamoto H, Inaba K, et al. CT based three dimensional dose-volume evaluations for high-dose rate intracavitary brachytherapy for cervical cancer. BMC cancer. 2014 Jun 17;14:447.
19. Charra-Brunaud C, Harter V, Delannes M, Haie-Meder C, Quetin P, Kerr C, et al. Impact of 3D image-based PDR brachytherapy on outcome of patients treated for cervix carcinoma in France: results of the French STIC prospective study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2012 Jun;103(3):305-13.
20. Fokdal L, Sturdza A, Mazeron R, Haie-Meder C, Tan LT, Gillham C, et al. Image guided adaptive brachytherapy with combined intracavitary and interstitial technique improves the therapeutic ratio in locally advanced cervical cancer: Analysis from the retroEMBRACE study. Radiother Oncol. 2016 Sep;120(3):434-40.
21. Nomden CN, de Leeuw AA, Moerland MA, Roesink JM, Tersteeg RJ, Jurgenliemk-Schulz IM. Clinical use of the Utrecht applicator for combined intracavitary/interstitial brachytherapy treatment in locally advanced cervical cancer. Int J Radiat Oncol Biol Phys. 2012 Mar 15;82(4):1424-30.
22. Beriwal S, Rwigema JC, Higgins E, Kim H, Houser C, Sukumvanich P, et al. Three-dimensional image-based high-dose-rate interstitial brachytherapy for vaginal cancer. Brachytherapy. 2012 May-Jun;11(3):176-80.
23. Duan J, Kim RY, Elassal S, Lin HY, Shen S. Conventional high-dose-rate brachytherapy with concomitant complementary IMRT boost: a novel approach for improving cervical tumor dose coverage. Int J Radiat Oncol Biol Phys. 2008 Jul 1;71(3):765-71.
24. Assenholt MS, Vestergaard A, Kallehauge JF, Mohamed S, Nielsen SK, Petersen JB, et al. Proof of principle: Applicator-guided stereotactic IMRT boost in combination with 3D MRI-based brachytherapy in locally advanced cervical cancer. Brachytherapy. 2014 Jul-Aug;13(4):361-8.
25. Klepczyk L, Shen S, Duan J, Kim RY. Image-Based Intracavitary Brachytherapy with Concurrent Applicator-Guided IMRT Boost for Cervical Cancer. Brachytherapy. 2013;12(Suppl 1):S56-S7.
26. Haie-Meder C, Potter R, Van Limbergen E, Briot E, De Brabandere M, Dimopoulos J, et al. Recommendations from Gynaecological (GYN) GEC-ESTRO Working Group (I): concepts and terms in 3D image based 3D treatment planning in cervix cancer brachytherapy with emphasis on MRI assessment of GTV and CTV. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2005 Mar;74(3):235-45.
27. Potter R, Haie-Meder C, Van Limbergen E, Barillot I, De Brabandere M, Dimopoulos J, et al. Recommendations from gynaecological (GYN) GEC ESTRO working group (II): concepts and terms in 3D image-based treatment planning in cervix cancer brachytherapy-3D dose volume parameters and aspects of 3D image-based anatomy, radiation physics, radiobiology. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology. 2006 Jan;78(1):67-77.
28. Vordermark D. Radiotherapy of Cervical Cancer. Oncol Res Treat. 2016;39(9):516-20.
29. Albuquerque K TV, Lea J, Ahn C, Richardson D, Miller D, Timmerman R. A Phase II Trial of Stereotactic Ablative Radiation Therapy as a Boost for Locally Advanced Cervical Cancer. Int J Radiat Oncol Biol Phys. 2020;106((3)):464-71. .
30. Alektiar KM. Can intensity-modulated radiation therapy replace brachytherapy in the management of cervical cancer? Point. Brachytherapy. 2002;1(4):191-2.
31. Dobelbower MC, Shen S, Popple R, Kim RY. Dosimetric comparison of IMRT to HDR intracavitary brachytherapy for cervical cancer. Brachytherapy. 2007;6(2).
32. Kilic S, Cracchiolo B, Mahmoud O. Non-brachytherapy alternative in cervical cancer radiotherapy: Why not? Applied radiation Oncology. 2015;4:11-7.
33.www.embracestudy.dk
34. Potter R, Tanderup K, Kirisits C, de Leeuw A, Kirchheiner K, Nout R, et al. The EMBRACE II study: The outcome and prospect of two decades of evolution within the GEC-ESTRO GYN working group and the EMBRACE studies. Clin Transl Radiat Oncol. 2018 Feb;9:48-60.
35. Assenholt MS, Petersen JB, Nielsen SK, Lindegaard JC, Tanderup K. A dose planning study on applicator guided stereotactic IMRT boost in combination with 3D MRI based brachytherapy in locally advanced cervical cancer. Acta Oncol. 2008;47(7):1337-43.
36. Yin G, Wang P, Lang J, Tian Y, Luo Y, Fan Z, et al. Dosimetric study for cervix carcinoma treatment using intensity modulated radiation therapy (IMRT) compensation based on 3D intracavitary brachytherapy technique. Journal of contemporary brachytherapy. 2016 Jun;8(3):221-32.
37. Wang X, Li J, Wang P, Yuan K, Yin G, Wan B. Image guided radiation therapy boost in combination with high-dose-rate intracavitary brachytherapy for the treatment of cervical cancer. J Contemp Brachytherapy. 2016 Apr;8(2):122-7.
38. Kirisits C, Potter R, Lang S, Dimopoulos J, Wachter-Gerstner N, Georg D. Dose and volume parameters for MRI-based treatment planning in intracavitary brachytherapy for cervical cancer. Int J Radiat Oncol Biol Phys. 2005 Jul 1;62(3):901-11.
39. Tanderup K, Potter R, Lindegaard JC, Berger D, Wambersie A, Kirisits C. PTV margins should not be used to compensate for uncertainties in 3D image guided intracavitary brachytherapy. Radiother Oncol. 2010 Dec;97(3):495-500.
40. Jurgenliemk-Schulz IM, Tersteeg RJ, Roesink JM, Bijmolt S, Nomden CN, Moerland MA, et al. MRI-guided treatment-planning optimisation in intracavitary or combined intracavitary/interstitial PDR brachytherapy using tandem ovoid applicators in locally advanced cervical cancer. Radiother Oncol. 2009 Nov;93(2):322-30.
41. Yoshida K, Yamazaki H, Kotsuma T, Takenaka T, Ueda MM, Miyake S, et al. Simulation analysis of optimized brachytherapy for uterine cervical cancer: Can we select the best brachytherapy modality depending on tumor size? Brachytherapy. 2016 Jan-Feb;15(1):57-64.
42. Dimopoulos JC, Lang S, Kirisits C, Fidarova EF, Berger D, Georg P, et al. Dose-volume histogram parameters and local tumor control in magnetic resonance image-guided cervical cancer brachytherapy. International journal of radiation oncology, biology, physics. 2009 Sep 1;75(1):56-63.
43. Lindegaard JC, Fokdal LU, Nielsen SK, Juul-Christensen J, Tanderup K. MRI-guided adaptive radiotherapy in locally advanced cervical cancer from a Nordic perspective. Acta Oncol. 2013 Oct;52(7):1510-9.
44. Potter R, Dimopoulos J, Georg P, Lang S, Waldhausl C, Wachter-Gerstner N, et al. Clinical impact of MRI assisted dose volume adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother Oncol. 2007 May;83(2):148-55.
45. Mazeron R, Fokdal LU, Kirchheiner K, Georg P, Jastaniyah N, Segedin B, et al. Dose-volume effect relationships for late rectal morbidity in patients treated with chemoradiation and MRI-guided adaptive brachytherapy for locally advanced cervical cancer: Results from the prospective multicenter EMBRACE study. Radiother Oncol. 2016 Sep;120(3):412-9.
46. Fokdal L, Potter R, Kirchheiner K, Lindegaard JC, Jensen NBK, Kirisits C, et al. Physician assessed and patient reported urinary morbidity after radio-chemotherapy and image guided adaptive brachytherapy for locally advanced cervical cancer. Radiother Oncol. 2018 Jun;127(3):423-30.